BMRN stock icon

BioMarin Pharmaceuticals
BMRN

$75.52
0.5%
 

About: BioMarin's focus is on rare-disease therapies. Genzyme markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU. Voxzogo (vosoritide) was approved in achondroplasia in 2021. BioMarin's Roctavian (hemophilia A gene therapy) was approved in Europe in 2022 and in the US in 2023.

Employees: 3,401

0
Funds holding %
of 6,656 funds
0
Analysts bullish %
of 14 analysts
0
News positive %
of 5 articles

Fund manager confidence

Based on 2023 Q4 SEC filings by fund managers ($100M+ AUM)

75% more call options, than puts

Call options by funds: $148M | Put options by funds: $84.6M

44% more first-time investments, than exits

New positions opened: 82 | Existing positions closed: 57

11% more capital invested

Capital invested by funds: $16.1B [Q3] → $17.8B (+$1.76B) [Q4]

5% more funds holding

Funds holding: 502 [Q3] → 527 (+25) [Q4]

3.5% more ownership

Funds ownership: 94.75% [Q3] → 98.24% (+3.5%) [Q4]

0% more funds holding in top 10

Funds holding in top 10: 16 [Q3] → 16 (+0) [Q4]

12% less repeat investments, than reductions

Existing positions increased: 173 | Existing positions reduced: 197

Research analyst outlook

14 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target
$72
5%
downside
Avg. target
$99
31%
upside
High target
$113
50%
upside

14 analyst ratings

positive
57%
neutral
43%
negative
0%
Baird
Joel Beatty
5%downside
$72
Neutral
Downgraded
17 May 2024
Evercore ISI Group
Cory Kasimov
50%upside
$113
Outperform
Initiated
14 May 2024
Morgan Stanley
Matthew Harrison
48%upside
$112
Overweight
Maintained
26 Apr 2024
Canaccord Genuity
Whitney Ijem
18%upside
$89
Hold
Maintained
26 Apr 2024
Citigroup
David Lebovitz
21%upside
$91
Neutral
Maintained
25 Apr 2024

Financial journalist opinion

Based on 5 articles about BMRN published over the past 30 days